Detalhe da pesquisa
1.
A phase II study of cabozantinib and pembrolizumab in advanced gastric/gastroesophageal adenocarcinomas resistant or refractory to immune checkpoint inhibitors.
Oncologist;
2024 Jun 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38823034
2.
Hereditary Cancer Clinics Improve Adherence to NCCN Germline Testing Guidelines for Pancreatic Cancer.
J Natl Compr Canc Netw;
: 1-7, 2024 Jun 18.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38889755
3.
Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib with Concurrent Radiation for Newly Diagnosed Resectable Rectal Cancer.
Oncologist;
23(1): 2-e5, 2018 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29158365
4.
Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08-20.
Oncologist;
22(10): 1158-e116, 2017 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28687627
5.
A case report of challenges in distinguishing gastroesophageal junction hepatoid adenocarcinoma from testicular germ cell tumor: Insights for improved diagnosis with gene expression profiling.
SAGE Open Med Case Rep;
12: 2050313X231223469, 2024.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38187811
6.
Case Report: A complete pathologic response in pancreatic cancer with squamous cell differentiation.
Front Oncol;
13: 1240405, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38094606
7.
Durable Responses in Patients With Advanced Cholangiocarcinoma on Sequential Dual-agent Immunotherapy After Progressing on Single-agent Immunotherapy.
Am J Clin Oncol;
45(10): 410-414, 2022 10 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36102355
8.
BRCA-Mutated Pancreatic Cancer: From Discovery to Novel Treatment Paradigms.
Cancers (Basel);
14(10)2022 May 16.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35626055
9.
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.
PLoS One;
17(10): e0276211, 2022.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36215283
10.
Financial Toxicity of Cancer Care: An Analysis of Financial Burden in Three Distinct Health Care Systems.
JCO Oncol Pract;
17(10): e1450-e1459, 2021 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33826366
11.
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.
PLoS One;
16(12): e0261994, 2021.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34941969
12.
Primary disseminated central neurocytoma: cytological and MRI evidence of tumor spread prior to surgery.
J Neurooncol;
100(2): 291-8, 2010 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20352470
13.
Medical oncology management of advanced hepatocellular carcinoma 2019: a reality check.
Front Med;
14(3): 273-283, 2020 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31863306
14.
MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer.
Clin Cancer Res;
25(10): 2988-2995, 2019 05 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30224341
15.
Phase II studies of antiangiogenic four drug regimens for the treatment of advanced renal cell carcinoma: FUNIL-retinoid and the FUNIL-thalidomide protocols.
Urol Oncol;
26(6): 610-5, 2008.
Artigo
em Inglês
| MEDLINE
| ID: mdl-18367103
16.
A Phase 2 Randomized, Double-Blind, Multicenter Trial of Imexon Plus Gemcitabine Versus Gemcitabine Plus Placebo in Patients With Metastatic Chemotherapy-naïve Pancreatic Adenocarcinoma.
Am J Clin Oncol;
41(3): 230-235, 2018 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26709865
17.
INST OX-05-024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial.
Cancer Med;
6(9): 2042-2051, 2017 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28801995
18.
Use of the 21-Gene Recurrence Score to Predict Clinical Outcomes in Early Breast Cancer.
JAMA Oncol;
6(4): 585-586, 2020 04 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32053140
19.
(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.
Eur J Cancer;
51(14): 1857-64, 2015 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26187510